A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia ...

AstraZeneca PLC ADR closed 14.96% below its 52-week high of $87.68, which the company achieved on August 30th.

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.

AstraZeneca PLC ADR closed 14.68% short of its 52-week high of $87.68, which the company achieved on August 30th.

Astrazeneca has defended the £14.7 million pay package handed to chief executive Pascal Soriot, saying the group is too big ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...